Report Detail
Global Prostate Cancer Hormone Therapy Market Growth (Status and Outlook) 2023-2029
- RnM4501029 |
- 10 January, 2023 |
- Global |
- 102 Pages |
- LPI(LP Information) |
- Other
LPI (LP Information)' newest research report, the “Prostate Cancer Hormone Therapy Industry Forecast” looks at past sales and reviews total world Prostate Cancer Hormone Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Hormone Therapy sales for 2023 through 2029. With Prostate Cancer Hormone Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Hormone Therapy industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer Hormone Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer Hormone Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer Hormone Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Hormone Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Hormone Therapy.
The global Prostate Cancer Hormone Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Prostate Cancer Hormone Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Prostate Cancer Hormone Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Prostate Cancer Hormone Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Prostate Cancer Hormone Therapy players cover Pfizer, Astellas, Johnson & Johnson, AstraZeneca, Bayer, Merck, Tolmar, Zoladex and Ferring Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Hormone Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Injection
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Astellas
Johnson & Johnson
AstraZeneca
Bayer
Merck
Tolmar
Zoladex
Ferring Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals
CTTQ
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Prostate Cancer Hormone Therapy Market Size 2018-2029
- 2.1.2 Prostate Cancer Hormone Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Prostate Cancer Hormone Therapy Segment by Type
- 2.2.1 Tablet
- 2.2.2 Injection
- 2.3 Prostate Cancer Hormone Therapy Market Size by Type
- 2.3.1 Prostate Cancer Hormone Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
- 2.3.2 Global Prostate Cancer Hormone Therapy Market Size Market Share by Type (2018-2023)
- 2.4 Prostate Cancer Hormone Therapy Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Others
- 2.5 Prostate Cancer Hormone Therapy Market Size by Application
- 2.5.1 Prostate Cancer Hormone Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
- 2.5.2 Global Prostate Cancer Hormone Therapy Market Size Market Share by Application (2018-2023)
3 Prostate Cancer Hormone Therapy Market Size by Player
- 3.1 Prostate Cancer Hormone Therapy Market Size Market Share by Players
- 3.1.1 Global Prostate Cancer Hormone Therapy Revenue by Players (2018-2023)
- 3.1.2 Global Prostate Cancer Hormone Therapy Revenue Market Share by Players (2018-2023)
- 3.2 Global Prostate Cancer Hormone Therapy Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Prostate Cancer Hormone Therapy by Regions
- 4.1 Prostate Cancer Hormone Therapy Market Size by Regions (2018-2023)
- 4.2 Americas Prostate Cancer Hormone Therapy Market Size Growth (2018-2023)
- 4.3 APAC Prostate Cancer Hormone Therapy Market Size Growth (2018-2023)
- 4.4 Europe Prostate Cancer Hormone Therapy Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Prostate Cancer Hormone Therapy Market Size Growth (2018-2023)
5 Americas
- 5.1 Americas Prostate Cancer Hormone Therapy Market Size by Country (2018-2023)
- 5.2 Americas Prostate Cancer Hormone Therapy Market Size by Type (2018-2023)
- 5.3 Americas Prostate Cancer Hormone Therapy Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Prostate Cancer Hormone Therapy Market Size by Region (2018-2023)
- 6.2 APAC Prostate Cancer Hormone Therapy Market Size by Type (2018-2023)
- 6.3 APAC Prostate Cancer Hormone Therapy Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Prostate Cancer Hormone Therapy by Country (2018-2023)
- 7.2 Europe Prostate Cancer Hormone Therapy Market Size by Type (2018-2023)
- 7.3 Europe Prostate Cancer Hormone Therapy Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Prostate Cancer Hormone Therapy by Region (2018-2023)
- 8.2 Middle East & Africa Prostate Cancer Hormone Therapy Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Prostate Cancer Hormone Therapy Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Prostate Cancer Hormone Therapy Market Forecast
- 10.1 Global Prostate Cancer Hormone Therapy Forecast by Regions (2024-2029)
- 10.1.1 Global Prostate Cancer Hormone Therapy Forecast by Regions (2024-2029)
- 10.1.2 Americas Prostate Cancer Hormone Therapy Forecast
- 10.1.3 APAC Prostate Cancer Hormone Therapy Forecast
- 10.1.4 Europe Prostate Cancer Hormone Therapy Forecast
- 10.1.5 Middle East & Africa Prostate Cancer Hormone Therapy Forecast
- 10.2 Americas Prostate Cancer Hormone Therapy Forecast by Country (2024-2029)
- 10.2.1 United States Prostate Cancer Hormone Therapy Market Forecast
- 10.2.2 Canada Prostate Cancer Hormone Therapy Market Forecast
- 10.2.3 Mexico Prostate Cancer Hormone Therapy Market Forecast
- 10.2.4 Brazil Prostate Cancer Hormone Therapy Market Forecast
- 10.3 APAC Prostate Cancer Hormone Therapy Forecast by Region (2024-2029)
- 10.3.1 China Prostate Cancer Hormone Therapy Market Forecast
- 10.3.2 Japan Prostate Cancer Hormone Therapy Market Forecast
- 10.3.3 Korea Prostate Cancer Hormone Therapy Market Forecast
- 10.3.4 Southeast Asia Prostate Cancer Hormone Therapy Market Forecast
- 10.3.5 India Prostate Cancer Hormone Therapy Market Forecast
- 10.3.6 Australia Prostate Cancer Hormone Therapy Market Forecast
- 10.4 Europe Prostate Cancer Hormone Therapy Forecast by Country (2024-2029)
- 10.4.1 Germany Prostate Cancer Hormone Therapy Market Forecast
- 10.4.2 France Prostate Cancer Hormone Therapy Market Forecast
- 10.4.3 UK Prostate Cancer Hormone Therapy Market Forecast
- 10.4.4 Italy Prostate Cancer Hormone Therapy Market Forecast
- 10.4.5 Russia Prostate Cancer Hormone Therapy Market Forecast
- 10.5 Middle East & Africa Prostate Cancer Hormone Therapy Forecast by Region (2024-2029)
- 10.5.1 Egypt Prostate Cancer Hormone Therapy Market Forecast
- 10.5.2 South Africa Prostate Cancer Hormone Therapy Market Forecast
- 10.5.3 Israel Prostate Cancer Hormone Therapy Market Forecast
- 10.5.4 Turkey Prostate Cancer Hormone Therapy Market Forecast
- 10.5.5 GCC Countries Prostate Cancer Hormone Therapy Market Forecast
- 10.6 Global Prostate Cancer Hormone Therapy Forecast by Type (2024-2029)
- 10.7 Global Prostate Cancer Hormone Therapy Forecast by Application (2024-2029)
11 Key Players Analysis
- 11.1 Pfizer
- 11.1.1 Pfizer Company Information
- 11.1.2 Pfizer Prostate Cancer Hormone Therapy Product Offered
- 11.1.3 Pfizer Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Pfizer Main Business Overview
- 11.1.5 Pfizer Latest Developments
- 11.2 Astellas
- 11.2.1 Astellas Company Information
- 11.2.2 Astellas Prostate Cancer Hormone Therapy Product Offered
- 11.2.3 Astellas Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Astellas Main Business Overview
- 11.2.5 Astellas Latest Developments
- 11.3 Johnson & Johnson
- 11.3.1 Johnson & Johnson Company Information
- 11.3.2 Johnson & Johnson Prostate Cancer Hormone Therapy Product Offered
- 11.3.3 Johnson & Johnson Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.3.4 Johnson & Johnson Main Business Overview
- 11.3.5 Johnson & Johnson Latest Developments
- 11.4 AstraZeneca
- 11.4.1 AstraZeneca Company Information
- 11.4.2 AstraZeneca Prostate Cancer Hormone Therapy Product Offered
- 11.4.3 AstraZeneca Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.4.4 AstraZeneca Main Business Overview
- 11.4.5 AstraZeneca Latest Developments
- 11.5 Bayer
- 11.5.1 Bayer Company Information
- 11.5.2 Bayer Prostate Cancer Hormone Therapy Product Offered
- 11.5.3 Bayer Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.5.4 Bayer Main Business Overview
- 11.5.5 Bayer Latest Developments
- 11.6 Merck
- 11.6.1 Merck Company Information
- 11.6.2 Merck Prostate Cancer Hormone Therapy Product Offered
- 11.6.3 Merck Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.6.4 Merck Main Business Overview
- 11.6.5 Merck Latest Developments
- 11.7 Tolmar
- 11.7.1 Tolmar Company Information
- 11.7.2 Tolmar Prostate Cancer Hormone Therapy Product Offered
- 11.7.3 Tolmar Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.7.4 Tolmar Main Business Overview
- 11.7.5 Tolmar Latest Developments
- 11.8 Zoladex
- 11.8.1 Zoladex Company Information
- 11.8.2 Zoladex Prostate Cancer Hormone Therapy Product Offered
- 11.8.3 Zoladex Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.8.4 Zoladex Main Business Overview
- 11.8.5 Zoladex Latest Developments
- 11.9 Ferring Pharmaceuticals
- 11.9.1 Ferring Pharmaceuticals Company Information
- 11.9.2 Ferring Pharmaceuticals Prostate Cancer Hormone Therapy Product Offered
- 11.9.3 Ferring Pharmaceuticals Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.9.4 Ferring Pharmaceuticals Main Business Overview
- 11.9.5 Ferring Pharmaceuticals Latest Developments
- 11.10 Jiangsu Hengrui Pharmaceuticals
- 11.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 11.10.2 Jiangsu Hengrui Pharmaceuticals Prostate Cancer Hormone Therapy Product Offered
- 11.10.3 Jiangsu Hengrui Pharmaceuticals Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.10.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
- 11.10.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
- 11.11 CTTQ
- 11.11.1 CTTQ Company Information
- 11.11.2 CTTQ Prostate Cancer Hormone Therapy Product Offered
- 11.11.3 CTTQ Prostate Cancer Hormone Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 11.11.4 CTTQ Main Business Overview
- 11.11.5 CTTQ Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Prostate Cancer Hormone Therapy. Industry analysis & Market Report on Prostate Cancer Hormone Therapy is a syndicated market report, published as Global Prostate Cancer Hormone Therapy Market Growth (Status and Outlook) 2023-2029. It is complete Research Study and Industry Analysis of Prostate Cancer Hormone Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
